๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Phase ii evaluation of a combination of mitomycin C, vincristine, and cisplatin in advanced non-small cell lung cancer

โœ Scribed by Alex Yuang-Chi Chang; J. Philip Kuebler; Douglass C. Tormey; Susan Anderson; Kishan J. Pandya; Ernest C. Borden; Thomas E. Davis; Donald L. Trump

Publisher
John Wiley and Sons
Year
1986
Tongue
English
Weight
606 KB
Volume
57
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Combination chemotherapy with mitomycin-
Combination chemotherapy with mitomycin-C, cisplatin, and vinblastine in the treatment of non-small-cell lung cancer
โœ Niell, Harvey B. ;Griffin, John P. ๐Ÿ“‚ Article ๐Ÿ“… 1985 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 443 KB

The drug combination of mitomycin-C, cisplatin, and vinblastine was administered to 30 patients with stage III non-small-cell lung cancer. All patients had a performance status of 50% or greater, had evaluable disease, and had not received previous chemotherapy. The overall response rate was 37% wit

Phase II trial of irinotecan, cisplatin
Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancer
โœ Dean A. Fennell; Jeremy P.C. Steele; Jonathan Shamash; Sarah E. Slater; Michael ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 87 KB ๐Ÿ‘ 1 views

## Abstract There is no standard therapy for relapsed small cell lung cancer (rSCLC). We evaluated the efficacy and toxicity of a new triplet consisting of irinotecan (100 mg/m^2^ Days 1 and 15 q28), cisplatin (40 mg/m^2^ Days 1 and 15 q28) and mitomycin (6 mg/m^2^ d1 q28) administered to a maximum